RxDoctor Payments Data

Sheldon Henry, MD

Cardiovascular Disease · Port Matilda, PANPI 1295704609

Payments from drug & device makers

$5,332in general payments, 2019–2025

Across 9 payments — averaging $592.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Novartis$73
  • Teleflex LLC$28
  • Actelion Pharmaceuticals US, Inc.$21
  • Johnson & Johnson$21
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16

What the payments were for

  • Food & beverage$159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,332 in reported general payments places this provider in the 70th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,581
Medicare patients
1,174
Services billed
3,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$200,172
Repatha SureclickEvolocumab57$52,662
JardianceEmpagliflozin41$52,184
EntrestoSacubitril/Valsartan38$45,185
XareltoRivaroxaban12$15,933
Metoprolol Succinate534$11,894
Praluent PenAlirocumab19$11,527
Rosuvastatin Calcium280$4,374
Ezetimibe122$3,584
Losartan Potassium204$3,265
Isosorbide Mononitrate ErIsosorbide Mononitrate94$1,860
Potassium Chloride40$1,838
Amlodipine Besylate219$1,570
Spironolactone159$1,459
Terazosin Hcl45$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$73$45,18538 claims
Johnson & JohnsonXarelto$21$15,93312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Port Matilda

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →